# Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction

Study · id `cardio:ct-nct05410925` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05410925](<https://clinicaltrials.gov/study/NCT05410925>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05410925

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2260 participants.

## Technical summary

Registry record NCT05410925. Randomized; quadruple masking; primary purpose treatment. Start 2023-04-08 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 2260 participants (planned count; ClinicalTrials.gov record NCT05410925, source copy `cardio:ctgov-nct05410925-2026-10-30`, retrieved 2026-10-31)
- Started: 2023-04-08 (actual) (ClinicalTrials.gov record NCT05410925, source copy `cardio:ctgov-nct05410925-2026-10-30`, retrieved 2026-10-31)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT05410925, source copy `cardio:ctgov-nct05410925-2026-10-30`, retrieved 2026-10-31)
- Completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT05410925, source copy `cardio:ctgov-nct05410925-2026-10-30`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT05410925, source copy `cardio:ctgov-nct05410925-2026-10-30`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05410925-2026-10-30`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction
- Acronym: OPTIMA-6
- Condition: ST Elevation Myocardial Infarction
- Intervention (Drug): Recombinant staphylokinase
- Intervention (Drug): Placebo
- Lead sponsor: The First Affiliated Hospital with Nanjing Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: The First Affiliated Hospital with Nanjing Medical University (`cardio:org-the-first-affiliated-hospital-with-nanjing-medical-898271`)

## Provenance

Content hash: 258d6491c170df5d4c6981b086c1b7cd334be91a7d0c0d754d1f9a66e473a180
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
